CIDP (chronic inflammatory demyelinating polyneuropathy) trials in Japan
7 of 7 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
- Where
- Bunkyo-ku, Hiroshima, Kōriyama, Saga
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- argenx
See details and how to joinNCT07091630 · EU 2025-520805-10-00 - Phase 2/3Taking peopleEfficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Where
- Asahikawa, Bunkyō City, Chiba, Hamamatsu, Isehara, Kobe, Kodaira-shi, Koshigaya, Kumamoto, Nagoya, Osaka Sayama Shi, Sendai, Shimotsuga-gun, Shinjuku-ku, Tenri, Toon-shi, Toyama, Ube
- Age
- 18 years and over
- People
- 201 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05327114 · EU 2023-508425-28-00 - Phase 3Taking peopleA Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- Where
- Aomori, Bunkyō City, Chūōku, Hiroshima, Izunokuni, Osaka, Saga, Shimotsuke, Tsuchiura, Ube
- Age
- 18 years and over
- People
- 218 worldwide
- Run by
- argenx
See details and how to joinNCT06920004 · EU 2024-520097-36-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
- Where
- Chiba, Hirakata, Kawagoe, Kawasaki, Kurashiki, Kyoto, Nagoya, Niigata, Sapporo, Tokyo, Tsukuba, Ube
- Age
- 18 years to 75 years
- People
- 256 worldwide
- Run by
- Dianthus Therapeutics
See details and how to joinNCT06858579 - Phase 3Enrolling by invitationLong-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
- Where
- Bunkyo-Ku, Higashi-Matsuyama, Kodaira
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Sanofi
See details and how to joinNCT06859099 · EU 2024-517032-22-00 - Phase 3Taking peopleA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Where
- Amagasaki, Chiba, Higashi-Matsuyama, Kawagoe, Kodaira, Ōta-ku, Saga, Yaizu, Yokohama
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT06290141 · EU 2023-508338-33-00 - Phase 3Taking peopleA Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Where
- Bunkyo-ku, Higashi-Matsuyama, Kashihara, Kumamoto, Nagoya, Ōtsu, Sendai, Tokushima
- Age
- 18 years and over
- People
- 59 worldwide
- Run by
- Takeda
See details and how to joinNCT06747351 · EU 2024-517450-95-00